Commentary

You have full text access to this OnlineOpen article

Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas

Changing the paradigms of treatments?

  1. Morton Coleman MD1,†,*,
  2. Lale Kostakoglu MD2

Article first published online: 24 AUG 2006

DOI: 10.1002/cncr.22178

Issue

Cancer

Cancer

Volume 107, Issue 7, pages 1425–1428, 1 October 2006

Additional Information

How to Cite

Coleman, M. and Kostakoglu, L. (2006), Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas. Cancer, 107: 1425–1428. doi: 10.1002/cncr.22178

Author Information

  1. 1

    Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York

  2. 2

    Department of Radiology, Mount Sinai Medical Center, New York, New York

  1. †

    Fax: (212) 734-9238

*Division of Hematology/Oncology, New York Presbyterian Hospital, Weill Cornell Medical Center, 407 East 70th Street, 3rd Floor, New York, NY 10021

Publication History

  1. Issue published online: 18 SEP 2006
  2. Article first published online: 24 AUG 2006
  3. Manuscript Accepted: 27 JUN 2006
  4. Manuscript Revised: 21 JUN 2006
  5. Manuscript Received: 26 APR 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (68K)

REFERENCES

  • 1
    Pasmantier MW, Coleman M, Silver RT. Chemotherapy of the non-Hodgkin's lymphomas. Med Clin North Am. 1976; 60: 1043–1052.
  • 2
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1998; 328: 1002–1006.
  • 3
    Pfreundschuh M, Kloess M, Schmits R, et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Session type: oral session. Blood (ASH Annual Meeting Abstracts). 2005; 106: 9a. Abstract 13.
  • 4
    Verdonck LF, van Imhoff GW, Raemakers JMM, et al. Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin lymphoma. Results of a prospective randomized HOVON trial. Blood (ASH Annual Meeting Abstracts). 2005; 106: 9a. Abstract 14.
  • 5
    Coleman M, Armitage JO, Gaynor M. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol. 1988; 25( Suppl 2): 23–33.
  • 6
    Armitage JO, Weisenburger DD, Hutchins M. Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol. 1986; 4: 160–164.
  • 7
    Engelhard M, Meusers P, Brittinger G. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol. 1991; 2: 177–180.
  • 8
    Haq R, Sawka CA, Franssen E. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol. 1994; 12: 1074–1084.
  • 9
    Coleman M, Rafla S, Propert KJ, et al. Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival—results of a Cancer and Leukemia Group B study. Int J Radiat Oncol Biol Phys. 1998; 41: 639–645.
  • 10
    Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 2002; 1(13 Suppl ): 86–91.
  • 11
    Canellos GP. Current strategies for early Hodgkin's disease. Ann Oncol. 1996; 7( Suppl 4): 91–93.
  • 12
    Fillet G, Bonnet C, Mounier N, et al. No role for chemoradiotherapy when compared with chemotherapy alone in elderly patients with localized low risk aggressive lymphoma: final results of the LNH93–4 GELA study. Session type: oral session. Blood (ASH Annual Meeting Abstracts). 2005; 106: 9a. Abstract 15.
  • 13
    Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for Stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004; 104: 3483–3489.
  • 14
    Longo DL. The case against the routine use of radiation therapy in advanced-stage Hodgkin's disease. Cancer Invest. 1996; 14: 353–360.
  • 15
    Coleman M, Gerstein G, Topilow A, et al. Advances in chemotherapy for large cell lymphoma. Semin Hematol. 1987; 24(2 Suppl 1 ): 8–20.
  • 16
    Fuks JZ, Aisner J, Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin lymphomas. Med Pediatr Oncol. 1982; 10: 429–438.
    Direct Link:
  • 17
    Surbone A, Longo DL, DeVita VTJr. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988; 6: 1832–1837.
  • 18
    Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemo therapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002; 43: 1018–1027.
  • 19
    Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000; 85: 613–618.
  • 20
    Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13: 1356–1363.
  • 21
    Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005; 16: 1514–1523.
  • 22
    Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106: 1376–1381.
  • 23
    Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107: 52–59.
  • 24
    Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94: 429–433.
  • 25
    Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001; 19: 414–419.
  • 26
    de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001; 12: 29–37.
  • 27
    Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001; 115: 793–800.
    Direct Link:
  • 28
    Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001; 98: 2930–2934.
  • 29
    Cremerius U, Fabry U, Neuerburg J, et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphomas. Nuklearmedizin. 2001; 40: 23–30.
  • 30
    Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004; 91: 850–854.
  • 31
    Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987–994.
  • 32
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 1506–1514.
  • 33
    Sehn LH, Chhanabhai M, Fitzgerald C, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP). Session type: oral session [abstract 492]. Blood (ASH Annual Meeting Abstracts). 2005; 106: 9a. Abstract 492.
  • 34
    Jerkeman M, Anderson H, Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study. Ann Hematol. 2004; 83: 414–419.
  • 35
    Juweid ME, Wiseman G, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyclucose positron emission tomography. J Clin Oncol. 2005; 23: 4652–4661.
  • 36
    Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol. 2004; 2: 115–121.
  • 37
    Kostakoglu L, Coleman M, Somrov S, et al. FDG-PET after one cycle of chemotherapy accurately predicts response to therapy in large cell (aggressive) non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). J Nucl Med. 2004; 45: 316P. Abstract.
  • 38
    Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after one cycle of therapy predicts outcome in diffuse large cell lymphoma and classical Hodgkin's disease. Cancer. In press.
  • 39
    Coleman M, Friedlander RJJr. Semantics and the chemotherapy of Hodgkin's disease—resistance is not relapse: alternative chemotherapy lacks effectiveness for disease not totally responsive to initial MOPP treatment. Cancer Invest. 1988; 6: 237–239.
View Full Article (HTML) Get PDF (68K)